Dong Shin

Summary

Affiliation: Emory University
Country: USA

Publications

  1. pmc Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis
    Xu Wang
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States of America
    PLoS ONE 9:e86369. 2014
  2. doi request reprint Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study
    Nabil F Saba
    Emory University School of Medicine, 1365 Clifton Road, Atlanta, GA 30322
    Cancer Prev Res (Phila) 7:283-91. 2014
  3. pmc Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity
    Debatosh Majumdar
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 C Clifton Road, Atlanta, GA 30322
    Cancer Prev Res (Phila) 7:65-73. 2014
  4. pmc New perspectives of curcumin in cancer prevention
    Wungki Park
    Department of Hematology and Medical Oncology, 1365 Clifton Road, C 3094, Winship Cancer Institute of Emory University, School of Medicine, Atlanta, GA, 30322, USA
    Cancer Prev Res (Phila) 6:387-400. 2013
  5. ncbi request reprint Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck
    Dong M Shin
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Head Neck 35:443-53. 2013
  6. pmc Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR
    Dongsheng Wang
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
    Mol Cancer 10:116. 2011
  7. pmc c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL
    Lei Fu
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia, USA
    Mol Cancer 9:315. 2010
  8. pmc Chemoprevention of head and neck cancer with green tea polyphenols
    Joseph W Kim
    Emory University, Atlanta, GA 30322, USA
    Cancer Prev Res (Phila) 3:900-9. 2010
  9. ncbi request reprint Oral cancer prevention advances with a translational trial of green tea
    Dong M Shin
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Cancer Prev Res (Phila) 2:919-21. 2009
  10. pmc Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer
    F Christopher Holsinger
    Emory Winship Cancer Institute, 1365 Clifton Rd, NE, Ste 3000, Atlanta, GA, 30322, USA
    J Clin Oncol 27:1976-82. 2009

Collaborators

Detail Information

Publications52

  1. pmc Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis
    Xu Wang
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States of America
    PLoS ONE 9:e86369. 2014
    ..These results suggest that targeting multidrug resistance using honokiol in combination with chemotherapy drugs may provide novel therapeutic opportunities...
  2. doi request reprint Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study
    Nabil F Saba
    Emory University School of Medicine, 1365 Clifton Road, Atlanta, GA 30322
    Cancer Prev Res (Phila) 7:283-91. 2014
    ..6 hours. Encouraging responses to the celecoxib and erlotinib combination correlated with EGFR pathway inhibition. Although erlotinib-related rash was the main limitation to dose escalation, the intervention was well tolerated...
  3. pmc Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity
    Debatosh Majumdar
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 C Clifton Road, Atlanta, GA 30322
    Cancer Prev Res (Phila) 7:65-73. 2014
    ..Our results suggest that nanoparticle delivery of naturally occurring dietary agents like luteolin has many advantages and may have potential application in chemoprevention in clinical settings...
  4. pmc New perspectives of curcumin in cancer prevention
    Wungki Park
    Department of Hematology and Medical Oncology, 1365 Clifton Road, C 3094, Winship Cancer Institute of Emory University, School of Medicine, Atlanta, GA, 30322, USA
    Cancer Prev Res (Phila) 6:387-400. 2013
    ..Here, we review the potential of curcumin in cancer prevention, its molecular targets, and mechanisms of action. Finally, we suggest specific recommendations to improve its efficacy and bioavailability for clinical applications...
  5. ncbi request reprint Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck
    Dong M Shin
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Head Neck 35:443-53. 2013
    ..Predictive biomarkers may help personalize therapy for SCCHN, and it is unclear whether the favorable prognostic effect of p16 or human papillomavirus in locally advanced oropharyngeal cancer is relevant for advanced disease...
  6. pmc Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR
    Dongsheng Wang
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
    Mol Cancer 10:116. 2011
    ..To understand the biological mechanisms underlying this clinical observation, we knocked down E-cad expression utilizing E-cad siRNA in four SCCHN cell lines...
  7. pmc c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL
    Lei Fu
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia, USA
    Mol Cancer 9:315. 2010
    ..The current study focuses on revealing the mechanisms by which perifosine enhances TRAIL-induced apoptosis...
  8. pmc Chemoprevention of head and neck cancer with green tea polyphenols
    Joseph W Kim
    Emory University, Atlanta, GA 30322, USA
    Cancer Prev Res (Phila) 3:900-9. 2010
    ..This review will provide an update of the potential of green tea polyphenols, particularly EGCG, for the chemoprevention of squamous cell carcinoma of the head and neck...
  9. ncbi request reprint Oral cancer prevention advances with a translational trial of green tea
    Dong M Shin
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Cancer Prev Res (Phila) 2:919-21. 2009
    ....
  10. pmc Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer
    F Christopher Holsinger
    Emory Winship Cancer Institute, 1365 Clifton Rd, NE, Ste 3000, Atlanta, GA, 30322, USA
    J Clin Oncol 27:1976-82. 2009
    ..Our objectives were to study the sensitivity of laryngeal cancer to platinum-based chemotherapy alone and to highlight the efficacy of CLS in this setting...
  11. pmc Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB
    A R M Ruhul Amin
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Cancer Prev Res (Phila) 2:538-45. 2009
    ..Characterizing the underlying mechanisms of EGCG and erlotinib synergism will provide an important rationale for chemoprevention or treatment trials using this combination...
  12. doi request reprint Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells
    Dong Hai Huang
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
    Nanotechnology 20:225102. 2009
    ..QD-based analysis facilitates the understanding of the features of EGFR-TKI-insensitive versus -sensitive cancer cells and may be used in the prediction of patient response to EGFR-targeted therapy...
  13. ncbi request reprint Emerging drugs for head and neck cancer
    John C Rhee
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Expert Opin Emerg Drugs 9:91-104. 2004
    ..Their potential is being tested in various settings, including chemoprevention, recurrent and metastatic disease and combination with radiation therapy and/or cytotoxic agents...
  14. pmc Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor
    Xin Zhang
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Int J Cancer 123:1005-14. 2008
    ..Our results suggest a synergistic antitumor effect of a combined treatment with EGCG and erlotinib, and provide a promising regimen for future chemoprevention and treatment of SCCHN...
  15. ncbi request reprint Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model
    Xin Zhang
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 11:6261-9. 2005
    ..However, an in vivo efficacy of this combined treatment in SCCHN has not been studied...
  16. ncbi request reprint Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck
    Zhuo Chen
    Department of Hematology Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    Clin Cancer Res 10:5930-9. 2004
    ..Simultaneously blocking both EGFR and Cox-2-mediated pathways may be an efficient means of inhibiting cancer cell growth in SCCHN...
  17. pmc Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer
    Carmen M Klass
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, Georgia 30322, USA
    Head Neck 31:1263-73. 2009
    ....
  18. pmc HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors
    Xu Wang
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, Georgia, USA
    ACS Nano 3:3165-74. 2009
    ..These results indicate that specific delivery of paclitaxel with a ternary structured nanoparticle (HFT-T) targeting FR-positive tumor is a promising strategy to enhance chemotherapy efficacy and minimize adverse effects...
  19. ncbi request reprint Concurrent platinum-based chemotherapy and simultaneous modulated accelerated radiation therapy for locally advanced squamous cell carcinoma of the tongue base
    Joshua D Lawson
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Head Neck 30:327-35. 2008
    ..Median dose and dose per fraction to sites of gross primary or nodal disease, clinically involved neck, and clinically uninvolved neck were 70.29 Gy (2.13 Gy/fx), 63.03 Gy (1.91 Gy/fx), and 57.75 Gy (1.75 Gy/fx), respectively...
  20. ncbi request reprint Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck
    Mi Sun Choe
    Department of Hematology Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia 30322, USA
    Clin Cancer Res 13:3015-23. 2007
    ..Therefore, we postulated that the addition of celecoxib and ZD1839 to docetaxel, a cytotoxic agent, might further increase antitumor activity...
  21. pmc Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53
    A R M Ruhul Amin
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA
    J Biol Chem 285:34557-65. 2010
    ....
  22. ncbi request reprint Correlation of protease-activated receptor-1 with differentiation markers in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis
    Xin Zhang
    Department of Hematology Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia 30322, USA
    Clin Cancer Res 10:8451-9. 2004
    ..Although the functions of PAR-1 in many normal cells, such as platelets and astrocytes, have been well studied, its roles in cancer progression and metastasis have not been fully elucidated, and studies to date appear contradictory...
  23. doi request reprint Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation
    Susan Muller
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA
    Cancer 113:97-107. 2008
    ....
  24. ncbi request reprint Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer
    Mi Sun Choe
    Department of Hematology Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Mol Cancer Ther 4:1448-55. 2005
    ....
  25. pmc Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells
    Yuhong Du
    Departments of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Recept Signal Transduct Res 29:182-94. 2009
    ..5). This technology is applicable to other oncogenic pathways for the discovery of novel therapeutic agents for the treatment of various cancers...
  26. pmc Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma
    Nabil F Saba
    Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, 30322, USA
    Cancer Prev Res (Phila) 2:823-9. 2009
    ..Further validation of COX-2 expression is needed in prospective ongoing chemoprevention trials...
  27. pmc Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia 30322, USA
    Cancer 116:3903-9. 2010
    ..The authors conducted a phase 1 and pharmacokinetic study of everolimus and docetaxel for recurrent NSCLC...
  28. pmc Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact
    Heath A Elrod
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia, United States of America
    PLoS ONE 5:e12178. 2010
    ..Taken together, we suggest that both DR5 and caspase-8 are involved in regulation of HNSCC metastasis. Our findings warrant further investigation on the dual role of caspase-8 in cancer development...
  29. pmc p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells
    Sumin Kang
    Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA
    J Clin Invest 120:1165-77. 2010
    ..Moreover, targeting RSK2 markedly attenuates in vitro invasion and in vivo metastasis of HNSCC cells, suggesting that RSK2 may represent a therapeutic target in the treatment of metastatic HNSCC...
  30. doi request reprint Prognostic accuracy of computed tomography findings for patients with laryngeal cancer undergoing laryngectomy
    Jonathan J Beitler
    Department of Radiation Oncology, Emory University School of Medicine, 1365 Clifton Rd NE, Atlanta, GA 30322 1013, USA
    J Clin Oncol 28:2318-22. 2010
    ..Our goal was to review the accuracy of preoperative computed tomography (CT) scanning in determining the necessity for initial laryngectomy for advanced laryngeal cancer...
  31. ncbi request reprint Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: a retrospective single-institution analysis
    Nabil F Saba
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University Atlanta, Georgia, USA
    Head Neck 31:1447-55. 2009
    ..We present outcome data from concurrent chemotherapy and intensity-modulated radiation therapy (IMRT) for squamous cell carcinoma (SCC) of the larynx and oropharyx...
  32. ncbi request reprint Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors
    Fadlo R Khuri
    Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Clin Cancer Res 10:2968-76. 2004
    ....
  33. ncbi request reprint Targeting angiogenesis in head and neck cancer
    Nabil F Saba
    Winship Cancer Institute, Emory University, Atlanta, GA 30308, USA
    Curr Cancer Drug Targets 7:643-9. 2007
    ..In this critical review, we give an overview of angiogenesis and its potential therapeutic targets, and we focus on its preclinical and clinical applications in SCCHN...
  34. ncbi request reprint Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis
    Xin Zhang
    Department of Hematology and Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Rd, NE, Building C, Atlanta, GA 30322, USA
    Clin Exp Metastasis 23:209-22. 2006
    ....
  35. ncbi request reprint Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients
    Fadlo R Khuri
    Winship Cancer Institute Emory University School of Medicine, Atlanta, GA 30322, USA
    J Natl Cancer Inst 98:441-50. 2006
    ..We conducted a phase III randomized trial of low-dose isotretinoin versus placebo in early-stage HNSCC patients to assess its effect on second primary tumor incidence and survival...
  36. ncbi request reprint Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer
    Nabil F Saba
    Medical Education, Hematology and Oncology, Emory University, Atlanta, Georgia, USA
    Oncology (Williston Park) 20:153-61; discussion 162, 166, 169 passim. 2006
    ..We attempt to give an overview of the EGFR function and biology, focusing on the most important clinical findings and applications of EGFR inhibitors in lung and head and neck cancer...
  37. pmc Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug
    Nabil F Saba
    Winship Cancer Institute at Emory University, Atlanta, Georgia, USA
    Head Neck 31:475-81. 2009
    ..We investigated expression levels of folate receptor in squamous cell carcinoma of the head and neck (SCCHN) to evaluate folate receptor as a target for nanotherapy...
  38. ncbi request reprint Prevention of head and neck cancer: current status and future prospects
    Sanjay Jain
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Curr Probl Cancer 28:265-86. 2004
  39. ncbi request reprint Moving toward bioadjuvant approaches to head and neck cancer prevention
    Nabil F Saba
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Int J Radiat Oncol Biol Phys 69:S132-5. 2007
    ..Natural compounds such as these with favorable long-term safety profiles might be particularly suited to the cancer prevention setting, in which patients will usually tolerate only moderate risk and toxicity...
  40. ncbi request reprint Down-regulation of S100A2 in lymph node metastases of head and neck cancer
    Xin Zhang
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    Head Neck 29:236-43. 2007
    ..S100A2, a putative tumor suppressor, has been found to be down-regulated in several types of primary tumor as compared with the normal tissue. Only a few reports have explored its expression status and function in metastasis...
  41. ncbi request reprint Induction of cell cycle arrest and apoptosis by a combined treatment with 13-cis-retinoic acid, interferon-alpha2a, and alpha-tocopherol in squamous cell carcinoma of the head and neck
    Xin Zhang
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Head Neck 29:351-61. 2007
    ..The present study was conducted in vitro to elucidate the mechanisms of anti-tumor activity of this 3-drug combination in squamous cell carcinoma of the head and neck (SCCHN)...
  42. ncbi request reprint CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models
    Younghyoun Yoon
    Department of Hematology Oncology, Winship Cancer Institute, Emory University, School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 67:7518-24. 2007
    ..injected. 686LN-Ms cells failed to metastasize in the CXCR4 antagonist-treated group, whereas they metastasized to the lungs in the control group. Our data indicate that CXCR4 is an important target to inhibit tumor progression in SCCHN...
  43. ncbi request reprint Cancer prevention with natural compounds
    Norleena P Gullett
    Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Semin Oncol 37:258-81. 2010
    ..Phytochemicals have great potential in cancer prevention because of their safety, low cost, and oral bioavailability. In this review, we discuss potential natural cancer preventive compounds and their mechanisms of action...
  44. ncbi request reprint Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
    Rajni Sinha
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 C Clifton Road, Room 3090, Atlanta, GA 30322, USA
    Mol Cancer Ther 5:1909-17. 2006
    ..In this article, we briefly discuss the use of bioconjugated nanoparticles for the delivery and targeting of anticancer drugs...
  45. pmc Targeted delivery of paclitaxel to tumor cells: synthesis and in vitro evaluation
    John M Ndungu
    Department of Chemistry, 1515 Dickey Drive, Emory University, Atlanta, Georgia 30322, USA
    J Med Chem 53:3127-32. 2010
    ..The activity order against PTX-sensitive KB 3-1 cells is C2'-PTX-FFRmk-fVIIa > PTX > C2'-PTX-FFRck. The C2' complex shows an IC(50) of 12 nM against the PTX-sensitive cell line and 130 nM against PTX-resistant cells...
  46. ncbi request reprint Current status and future perspectives of chemoprevention in head and neck cancer
    Carmen M Klass
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Curr Cancer Drug Targets 7:623-32. 2007
    ....
  47. doi request reprint Application of nanotechnology in cancer therapy and imaging
    Xu Wang
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
    CA Cancer J Clin 58:97-110. 2008
    ..Therefore, their application as cancer cell-specific delivery vehicles will be a significant addition to the currently available armory for cancer therapeutics and imaging...
  48. ncbi request reprint Nanotechnology for targeted cancer therapy
    May D Wang
    Georgia Institute of Technology, Department of Biomedical Engineering, and Emory University, Atlanta, GA 30332, USA
    Expert Rev Anticancer Ther 7:833-7. 2007
    ....
  49. ncbi request reprint Therapeutic nanoparticles for drug delivery in cancer
    Kwangjae Cho
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 14:1310-6. 2008
    ..Multifunctional and multiplex nanoparticles are now being actively investigated and are on the horizon as the next generation of nanoparticles, facilitating personalized and tailored cancer treatment...
  50. pmc Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy
    Xiang Hong Peng
    Department of Medical Oncology Hematology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Int J Nanomedicine 3:311-21. 2008
    ..We review recent advances in the development of targeted IO nanoparticles for tumor imaging and therapy...
  51. ncbi request reprint In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags
    Ximei Qian
    Departments of Biomedical Engineering and Chemistry, Emory University and Georgia Institute of Technology, 101 Woodruff Circle, Suite 2001, Atlanta, Georgia 30322, USA
    Nat Biotechnol 26:83-90. 2008
    ....
  52. pmc Perspectives for cancer prevention with natural compounds
    A R M Ruhul Amin
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    J Clin Oncol 27:2712-25. 2009
    ..In this review, we discuss promising natural chemopreventive compounds, their molecular targets, and their mechanisms, which may help the further design and conduct of preclinical and clinical trials...

Research Grants8

  1. RANDOMIZED ADJUVANT THERAPY OF HEAD AND NECK CANCER
    Dong Shin; Fiscal Year: 2001
    ....
  2. RANDOMIZED ADJUVANT THERAPY OF HEAD AND NECK CANCER
    Dong Shin; Fiscal Year: 2000
    ....
  3. Second Primary Tumor Prevention w/EGFR TKIs & COX-2 inhibitors in H & N Cancer
    Dong Shin; Fiscal Year: 2006
    ..The clinical trial and biomarker studies will be conducted with various methodologies, including pharmacokinetic studies, immunohistochemistry, immunoblot, RT-PCR, IMCPL monitoring, and statistical analyses. ..
  4. Second Primary Tumor Prevention w/EGFR TKIs, COX-2 inhibitors Head & Neck Cancer
    Dong Shin; Fiscal Year: 2007
    ..The clinical trial and biomarker studies will be conducted with various methodologies, including pharmacokinetic studies, immunohistochemistry, immunoblot, RT-PCR, IMCPL monitoring, and statistical analyses. ..
  5. Second Primary Tumor Prevention w/EGFR TKIs, COX-2 inhibitors Head & Neck Cancer
    Dong Shin; Fiscal Year: 2008
    ..The clinical trial and biomarker studies will be conducted with various methodologies, including pharmacokinetic studies, immunohistochemistry, immunoblot, RT-PCR, IMCPL monitoring, and statistical analyses. ..
  6. Chemoprevention of Head and Neck Cancer with ZD1839 and Celecoxib
    Dong Shin; Fiscal Year: 2008
    ..Biomarker changes will be correlated with cancer incidence by statistical analyses. We will also determine whether such biomarker changes can serve as intermediate endpoint(s) in this chemopreventive trial. ..
  7. Second Primary Tumor Prevention w/EGFR TKIs, COX-2 inhibitors Head & Neck Cancer
    Dong Shin; Fiscal Year: 2009
    ..The clinical trial and biomarker studies will be conducted with various methodologies, including pharmacokinetic studies, immunohistochemistry, immunoblot, RT-PCR, IMCPL monitoring, and statistical analyses. ..